This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Welcome to
InOncology.com

Explore InOncology.com to find out how Boehringer Ingelheim is taking cancer on. Our goal is to develop innovative, first-in-class treatments that can transform the lives of patients and help win the fight against cancer. To achieve this, we are searching for, developing and accelerating novel therapeutic approaches to address the current unmet needs in both lung and gastrointestinal cancers.

Rate this
Franchise video homepage

RESOURCES

LATEST CONGRESSES: OUR ACTIVITIES

Past event
ASCO 2019
ASCO 2019
Access materials presented at ASCO; 5 publications and 5 downloads
Past event
WCLC 2019
WCLC 2019
Access materials presented at WCLC; 8 publications and 8 downloads
Past event
ESMO 2019
ESMO 2019
Access materials presented at ESMO; 6 publications and 10 downloads

Physicians´ insights

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

**Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

^Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: February 2020